Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
stocks
Weekly earnings wrap: FMG, WDS, COL and more
A closer look at the final major results from August reporting season.
stocks
Chart of the Week: Are US mega-cap stocks undervalued?
Opportunities emerge across US equities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.00 | 19.60 | 0.21% |
| CAC 40 | 8,319.87 | 142.52 | -1.68% |
| DAX 40 | 26,367.24 | 81.28 | 0.31% |
| Dow JONES (US) | 53,569.44 | 105.56 | 0.20% |
| FTSE 100 | 10,792.54 | 85.58 | -0.79% |
| HKSE | 25,565.74 | 87.23 | -0.34% |
| NASDAQ | 26,541.35 | 411.15 | 1.57% |
| Nikkei 225 | 66,523.18 | 391.20 | 0.59% |
| NZX 50 Index | 13,912.79 | 32.74 | 0.24% |
| S&P 500 | 7,730.99 | 55.29 | 0.72% |
| S&P/ASX 200 | 9,072.20 | 20.90 | 0.23% |
| SSE Composite Index | 3,956.57 | 44.05 | 1.13% |